Selected Grants
Nurse LEADS: Training in Nurse-LEd models of care ADdressing the Social Determinants of Health
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2024 - 2029Predictors of Pain Severity and Pain-Related Outcomes in Individuals with Sickle Cell Disease
ResearchMentor · Awarded by National Heart, Lung, and Blood Institute · 2023 - 2028REAL (Registry Expansion Analysis to Learn) Answers
ResearchCo Investigator · Awarded by Icahn School of Medicine at Mount Sinai · 2023 - 2028U2C/TL1 NC KUH TRIO Administrative Core
ResearchPreceptor · Awarded by University of North Carolina - Chapel Hill · 2023 - 2028TRIO NRSA Training Core-Pre Doc Trainee
Inst. Training Prgm or CMEPreceptor · Awarded by University of North Carolina - Chapel Hill · 2023 - 2028Point of care diagnostic for sickle cell disease
ResearchCo Investigator · Awarded by National Institutes of Health · 2024 - 2027GBT 440-4R2 Prospective Registry
Clinical TrialPrincipal Investigator · Awarded by Global Blood Therapeutics, Inc. · 2021 - 2026Hematology & Transfusion Medicine (T32)
Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 1975 - 2026Hybrid Effectiveness-Implementation Trial of Guided Relaxation and Acupuncture for Chronic Sickle Cell Disease Pain
Clinical TrialPrincipal Investigator · Awarded by University of Illinois at Chicago · 2020 - 2025Central Carolinas Clinical Trials Collaboration (C3TC)
ResearchCo Investigator · Awarded by American Society of Hematology · 2021 - 2025Insights into contraception use among Women with sickle cell disease: Identifying patient-perceived influential factors and reproductive health gaps through focus groups
ResearchMentor · Awarded by Foundation for Women & Girls with Blood Disorders · 2024 - 2025AKIRA Bio study
Clinical TrialPrincipal Investigator · Awarded by AkiraBio, Inc · 2022 - 2025A Phase II trial of topical sodium nitrite in patients with sickle cell disease and leg ulcers Cost Reimbursable
Clinical TrialHematologist · Awarded by Food and Drug Administration · 2021 - 2024GBT 440-4R1 Retrospective Registry
ResearchPrincipal Investigator · Awarded by Global Blood Therapeutics, Inc. · 2021 - 2024GBT-2104-132
Clinical TrialPrincipal Investigator · Awarded by Global Blood Therapeutics, Inc. · 2021 - 2024Epigenetic Age Acceleration and Psychoneurological Symptoms in Sickle Cell Disease
ResearchCo Investigator · Awarded by National Institutes of Health · 2022 - 2024An Open-Label, Expanded Access Protocol for Patients with Sickle Cell Disease Who Have No Alternative Treatment Options - GBT 440-037
Clinical TrialPrincipal Investigator · Awarded by Global Blood Therapeutics, Inc. · 2019 - 2023GBT440-039 A Phase 4, Multicenter, Open-label Study to Evaluate the Treatment Effect of Voxelotor on Physical Activity in Adolescents and Adults with Sickle Cell Disease
Clinical TrialPrincipal Investigator · Awarded by Global Blood Therapeutics, Inc. · 2020 - 2023SCH: INT: Collaborative Research: Development and analysis of integrative models for chronic pain
ResearchPrincipal Investigator · Awarded by Northwestern University · 2018 - 2023Improving SCD Care using Web-based Guidelines, Nurse Care Managers and Peer Mentors in Parimary Care Emergency Departments in Central North Carolina
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2016 - 2023Sickle Cell Disease Structured Transition Education Intervention With Peer Mentoring Support to Improving Care Transitions (SCD ST3P-UP Program)
ResearchPrincipal Investigator · Awarded by Charlotte-Mecklenburg Hospital Authority · 2018 - 2023An Open label extension study of GBT440 administered orally to patients with sickle cell disease who have participated in GBT440 clinical trials
Clinical TrialPrincipal Investigator · Awarded by Global Blood Therapeutics, Inc. · 2018 - 2022Disseminating NIH Evidence Based Sickle Cell Recommendations in North Carolina
ResearchCo Investigator · Awarded by Agency for Healthcare Research and Quality · 2016 - 2021A Phase 2a, Randomised, Double Blind, Placebo-Controlled Study of IMR-687 in Adult Patients with Sickle Cell Anaemia (Homozygous HbSS or Sickle-B thalassemia.
Clinical TrialPrincipal Investigator · Awarded by Imara, Inc. · 2019 - 2020A Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Subjects with Sickle Cell Disease
Clinical TrialPrincipal Investigator · Awarded by Global Blood Therapeutics, Inc. · 2017 - 2020Technology-Mediated Symptom Management in Pediatric Blood and Marrow Transplant Care
FellowshipCo-Sponsor · Awarded by National Institutes of Health · 2018 - 2020Impact of Sickle-Trait on Transcriptional Regulation in P. Falciparum Parasites
ResearchCollaborator · Awarded by National Institutes of Health · 2017 - 2020AZD9668 and Neutrophil Elastase Inhibition to Prevent Graft-versus-Host Disease
ResearchCo Investigator · Awarded by National Institutes of Health · 2018 - 2019Open Label study to evaluate the safety and Pharmacokinetics of PF-06412528 in children 7-17 for treatment of moderate to severe pain
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2018 - 2019DU176b-A-U157/ A Phase 1, Open-Label, Single-Dose Non-Randomized Study To Evaluate Pharmacokinetics And Pharmacodynamics of Edoxaban In Pediatric Patients
Clinical TrialPrincipal Investigator · Awarded by Daiichi Sankyo Inc · 2015 - 2019SUCCESSOR Chart Review
ResearchPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2018 - 2019Use of Mobile Technology to Improve Acute Care Utilization in Sickle Cell Disease
ResearchPrincipal Investigator · Awarded by Agency for Healthcare Research and Quality · 2015 - 2018Multicenter, open-label, active-controlled, randomized study to evaluate the efficacy and safety of an age- and body-weight-adjusted rivaroxaban regimen in children with acute venous thromboembolism
Clinical TrialPrincipal Investigator · Awarded by Bayer Healthcare Pharmaceuticals Inc · 2015 - 2018Improving Pain in Sickle Cell Patients With Targeted Antithrombotic Therapy
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2014 - 2017Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC): A Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial of MSY-188 injection in children with Sickle Cell disease experiencing vaso-occlusive crisis.
Clinical TrialPrincipal Investigator · Awarded by : Mast Therapeutics, Inc. · 2014 - 2017MST-188-04 EVALUATION OF REPEAT ADMINISTRATION OF PURIFIED POLOXAMER 188 IN VASO-OCCLUSIVE CRISIS OF SICKLE CELL DISEASE (EPIC-E): AN OPEN-LABEL SAFETY EXTENSION TRIAL ASSESSING REPEAT ADMINISTRATION OF MST-188 (PURIFIED POLOXAMER 188) INJECTION IN
Clinical TrialPrincipal Investigator · Awarded by Mast Therapeutics, Inc. · 2016 - 2017SUSTAIN (A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SEIGI With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises
Clinical TrialPrincipal Investigator · Awarded by Selexys Pharmaceuticals, Corp · 2014 - 2017QuBBD: Collaborative Research: Advancing mHealth using Big Data Analytics: Statistical and Dynamical Systems Modeling of Real-Time Adaptive m-Intervention for Pain
ResearchPrincipal Investigator · Awarded by National Science Foundation · 2015 - 2016Impact of Daily Prophylaxis Dose Anticoagulation with a Factor Xa Inhibitor (Apixaban) in Patients with Sickle Cell Disease
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb · 2013 - 2016Use of Mobile Technology for Intensive Training in Medication Management
ResearchPrincipal Investigator · Awarded by Sickle Soft Incorporated · 2014 - 2016Population-based Surveillance And Outcomes of Venous Thromboembolism
ResearchCo Investigator · Awarded by Centers for Disease Control and Prevention · 2012 - 2015External Relationships
- Alexion Pharmaceuticals, Inc. a subsidiary of AstraZeneca
- Bluebird bio
- Emmaus Pharmaceuticals/Chiesi
- Global Blood Therapeutics/Pfizer
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.